Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Medical - Instruments & Supplies

Healthcare
$3.60 +2.30%

+$0.37 today

Market cap
$158.01M
Beta
4.34
P/E (TTM)
99.1
EPS (TTM)
$0.16
52W Low $10.50High $55.65

Volume 0.09M

Average 0.03M

NNNN Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

Anbio Biotechnology Class A Ordinary SharesNASDAQ: NNNN

Deferred Income Tax · Q4 FY2024 · quarter ended Dec 2024

Deferred income tax outflow grows to $0

Q4 FY2024 deferred income tax was $0, compared with $0 a year earlier.

Context

  • Deferred income tax amounted to 0.0% of revenue in FY2025, unchanged from a year earlier.
  • Deferred income tax increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2024
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Income Tax vs competitors

How NNNN compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred income tax is compared through growth and share of revenue rather than absolute size.
  • Deferred income tax amounts to 0.0% of revenue for NNNN, versus a peer median of 0.1%.
NNNN Competitors
Deferred Income Tax for NNNN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$243.28M USD——81.2%
CYHCommunity Health Systems, Inc.LTM Mar 2026$217M USD+69.5%—1.0%
SNDLSNDL Inc.LTM Mar 2026CA$1.5M CAD-76.6%—0.2%
TALKTalkspace, Inc.LTM Mar 2026$472.84K USD——0.2%
ANGOAngioDynamics, Inc.LTM Feb 2026$200K USD-87.7%-35.7%0.1%
NNNNAnbio Biotechnology Class A Ordinary SharesFY2025$0 USD——0.0%
KALVKalVista Pharmaceuticals, Inc.LTM Dec 2025$0 USD——0.0%
CMPSCOMPASS Pathways plcLTM Mar 2026$0 USD———
AVNSAvanos Medical, Inc.LTM Mar 2026$0 USD——0.0%
CLPTClearPoint Neuro, Inc.LTM Mar 2026$0 USD——0.0%
GOSSGossamer Bio, Inc.LTM Mar 2026$0 USD——0.0%
Peer median (excluding NNNN) —-76.6%-35.7%0.1%

Competitors are the stored peer set for NNNN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income2.54M10.01M2.25M2.37M6.4M
Depreciation & Amortization06.25K12.06K00
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital1.65M(5.53M)(1.2M)44.65K(13.21M)
Accounts Receivables(717.5K)717.5K(1.88M)820.17K(2.59M)
Inventory0(353.87K)353.87K00
Accounts Payables1.89M(481.82K)(580.89K)798.1K(1.63M)
Other Working Capital473.15K(5.41M)907.97K(1.57M)(8.99M)
Other Non-Cash Items1(40.87K)(163.39K)(337.1K)68K
Operating Cash Flow4.18M4.45M898.37K2.08M(6.74M)
Capital Expenditures0(3)000
Acquisitions (Net)00000
Purchases of Investments0(16.09M)(18.54M)(35.47M)(19.42M)
Sales of Investments014.56M20.27M35.8M15.22M
Other Investing Activities00000
Investing Cash Flow0(1.53M)1.73M337.1K(4.2M)
Debt Repayment00000
Common Stock Issued00007.23M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(42.84K)(344.61K)(282.55K)
Financing Cash Flow00(42.84K)(344.61K)6.95M
Effect of Forex Changes00000
Net Change in Cash4.18M2.92M2.59M2.07M(3.99M)
Free Cash Flow4.18M4.45M898.37K2.08M(6.74M)

Anbio Biotechnology Class A Ordinary Shares

NASDAQ:NNNN

Intrinsic Alpha fair value

Locked

Current Price

$3.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.